Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ₹184.81 ₹154.97 ₹32.10 ₹251.58
2024 ₹206.45 ₹175.85 ₹34.44 ₹339.25
2025 ₹322.58 ₹261.43 ₹28.13 ₹455.49
Dec 2025 ₹236.50 ₹186.96 ₹38.69 ₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (₹) EPS basic (₹)Ā  EPS Diluted (₹) RONW (%) P/E Ratio NAV (₹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ₹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ₹326 to ₹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ₹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Mamata Machinery IPO Date, Review, Price, Allotment Details

Mamata Machinery IPO open date is December 19, 2024 and the IPO will close on December 23, 2024. Mamata Machinery IPO is a Book Built Issue. The company to raise around ₹179.39 crores via IPO that comprises fresh issue of ₹[.] crores and offer for sale up to 73,82,340 equity shares with face value of ₹10 each.

Mamata Machinery IPO price band is ₹230 to ₹243 per share. The retail quota is 35%, QIB is 50%, and HNI is 15%. Mamata Machinery IPO to list on BSE & NSE on December 27, 2024. The allotment of Mamata Machinery IPO date is December 24, 2024.

The company reported revenue of ₹241.31 crores in 2024 against ₹210.13 crore in 2023. The company reported Profit of ₹36.13 crores in 2024 against Profit of ₹22.51 crores in 2023. As per the financials the IPO investors should apply the IPO for a long term.

Mamata Machinery IPO

Mamata Machinery IPO Details

IPO Open Date:December 19, 2024
IPO Close Date:December 23, 2024
Face Value:₹10 Per Equity Share
IPO Price Band:₹230 to ₹243 Per Share
Issue Size:Approx ₹179.39 Crores
Offer for Sale:Approx 73,82,340 Equity Shares
Issue Type:Book Built Issue
IPO Listing:BSE & NSE
Employee Discount:₹12 Per Share
Retail Quota:Not more than 35%
QIB Quota:Not more than 50%
NII Quota:Not more than 15%
DRHP Draft Prospectus:Click Here
RHP Draft Prospectus:Click Here
Anchor Investors List:Click Here

Mamata Machinery IPO Market Lot

The Mamata Machinery IPO minimum market lot is 61 shares with ₹14,823 application amount. The retail investors can apply up-to 13 lots with 793 shares or ₹192,699 amount.

ApplicationLot SizeSharesAmount
Retail Minimum161₹14,823
Retail Maximum13793₹1,92,699
S-HNI Minimum14854₹2,07,522
B-HNI Minimum684,148₹10,07,964

Mamata Machinery IPO Dates

The Mamata Machinery IPO date is December 19, 2024 and the close date is December 23, 2024. The Mamata Machinery IPO allotment will be finalized on December 24, 2024 and the IPO listing on December 27, 2024.

IPO Open Date:December 19, 2024
IPO Close Date:December 23, 2024
Basis of Allotment:December 24, 2024
Refunds:December 26, 2024
Credit to Demat Account:December 26, 2024
IPO Listing Date:December 27, 2024

Promoters of Mamata Machinery IPO

The promoters of the company are Mahendra Patel, Chandrakant Patel, Nayana Patel, Bhagvati Patel, Mamata Group Corporate Services LLP, and Mamata Management Services LLP.

About Mamata Machinery IPO

Mamta Manufacturing was founded in 1979, focusing on making and exporting plastic pouch sealing machines, packing machinery, plastic bags, and extrusion equipment. The company primarily provides its packaging machinery to brands in the FMCG, food, and beverage sectors. The company has provided machines to over 75 countries, with 800 machines in operation across Africa, 100 machines in the USA supported by two offices representing its global network, and 100 machines in India. To establish itself as a globally recognized leader in the flexible packaging industry is a vision of this company. There has been a fluctuation in expenses from 2021 to 2024, with expenses recorded at 131.26 crores in 2021, 167.03 crores in 2022, 181.61 crores in 2023, and 131.44 crores in the current year, 2024. The revenue for FY 2024 is 148.25 crores. It has decided to launch an IPO of 73,82,340 shares which is totally OFS(Offer For Sale).

Mamata Machinery IPO Company Financial Report

The company reported revenue of ₹241.31 crores in 2024 against ₹210.13 crore in 2023. The company reported Profit of ₹36.13 crores in 2024 against Profit of ₹22.51 crores in 2023.

Amount ₹ in Crores

Period EndedRevenueExpenseProfit After TaxAssets
2022₹196.57₹167.03₹21.70₹216.33
2023₹210.13₹181.61₹22.51₹228.47
2024₹241.31₹194.38₹36.13₹237.49
June 2024₹29.19₹28.87₹0.22₹240.85

Mamata Machinery IPO Valuation – FY2024

Check Mamata Machinery IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

KPIValues
ROE:27.76%
ROCE:31.29%
EBITDA Margin:19.94%
PAT Margin:15.27%
Debt to equity ratio: 0.09
Earning Per Share (EPS):₹14.65 (Basic)
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):27.39%
Net Asset Value (NAV):₹53.59

Peer Group Comparison

CompanyEPSPE RatioRoNW %NAVIncome
Rajoo Engineers Limited3.4157.1616.5920.59201.29 Cr.
Windsor Machines Limited(1.19)NA(2.89)41.07356.92 Cr.
Kabra Extrusion Technik Limited9.8030.647.48134.52614.66 Cr.

Objects of the Issue

  • Carry out the Offer for Sale of up to 7,382,340 Equity Shares by the Selling Shareholders; and
  • Achieve the benefits of listing the Equity Shares on the Stock Exchanges.

Mamata Machinery IPO Review

Read the article on Mamata Machiery IPO Review – Apply or Not?

  • IPO Watch – May Apply
  • Canara Bank –
  • DRChoksey FinServ –
  • Emkay Global –
  • Hem Securities –
  • IDBI Capital –
  • Marwadi Shares –
  • Nirmal Bang –
  • SBICAP Securities –
  • Sharekhan –
  • SMC Global –
  • Sushil Finance –
  • Swastika Investmart –
  • Ventura Securities –
  • Geojit –
  • Reliance Securities –
  • Capital Market –
  • BP Wealth –
  • ICICIdirect –
  • Choice Broking –

Mamata Machinery IPO Registrar

Link Intime India Private Limited
C-101, 1st Floor, 247 Park L.B.S. Marg,
Vikhroli West, Mumbai – 400 083, Maharashtra
Phone: +91 22 4918 6200
Email: mamatamachinery.ipo@linkintime.co.in
Website: www.linkintime.co.in

IPO Lead Managers aka Merchant Bankers

  • Beeline Capital Advisors Private Limited

Company Address

Mamata Machinery Limited
Survey No. 423/P, Sarkhej-Bavla Road, N.H No. 8A,
Moraiya, Sanand, Ahmedabad, Gujarat – 382213
Phone: 02717–630 800/801
Email: cs@mamata.com
Website: www.mamata.com

Mamata Machinery IPO FAQs

What is Mamata Machinery IPO?

Mamata Machinery IPO is a main-board IPO. The company is going to raise ₹179.39 Crores via IPO. The issue is priced at ₹230 to ₹243 per equity share. The IPO is to be listed on BSE & NSE.

When Mamata Machinery IPO will open for subscription?

The IPO is to open on December 19, 2024 for QIB, NII, and Retail Investors. The IPO will close on December 23, 2024.

What is Mamata Machinery IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Mamata Machinery IPO?

You can apply for Mamata Machinery IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

What is Mamata Machinery IPO Issue Size?

Mamata Machinery IPO issue size is ₹179.39 crores.

What is Mamata Machinery IPO Price Band?

Mamata Machinery IPO Price Band is ā‚¹230 to ₹243.

What is Mamata Machinery IPO Lot Size?

The minimum bid is 61 Shares with ₹14,823 amount.

What is the Mamata Machinery IPO Allotment Date?

Mamata Machinery IPO allotment date is Deecember 24, 2024.

What is the Mamata Machinery IPO Listing Date?

Mamata Machinery IPO listing date is December 27, 2024. The IPO is to list on BSE & NSE.

Note: The Mamata Machinery IPO price band and date are officially announced. The (Mamata Machinery IPO grey market premium) will be added to the IPO GMP page as it will start).

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

3 Responses